Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Re-evaluating neuroleptics: their antipsychotic properties?]

D Ginestet1

  • 1Service de Psychiatrie, Université Paris XI, Hôpital Paul Brousse, Villejuif.

Presse Medicale (Paris, France : 1983)
|January 29, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychometric qualities of the French version of the Heinrichs quality of life rating scale.

European psychiatry : the journal of the Association of European Psychiatrists·2000
Same author

Efficacy of tianeptine in major depressive disorders with or without melancholia.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·1997
Same author

Comorbidity of personality disorders and unipolar major depression: a review.

Journal of affective disorders·1996
Same author

[Comorbidity in a sample of hospitalized depressed patients].

L'Encephale·1996
Same author

[Drugs diverted from reaching drug addicts].

La Revue du praticien·1995
Same author

Time course of prefrontal lobe dysfunction in severely depressed in-patients: a longitudinal neuropsychological study.

Psychological medicine·1995
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

New antipsychotics offer improved efficacy and fewer side effects compared to traditional neuroleptics, particularly for productive schizophrenia symptoms. Long-term safety and cost-effectiveness require further investigation for these advanced treatments.

Area of Science:

  • Pharmacology
  • Neuroscience

Context:

  • Traditional neuroleptics have limitations, including unsatisfactory response rates in ~25% of patients and significant neurological side effects.
  • Antipsychotics represent a newer class of drugs with distinct receptor profiles.

Purpose:

  • To compare the properties and clinical effects of traditional neuroleptics and newer antipsychotic medications.
  • To highlight the advantages of antipsychotics, such as reduced extrapyramidal effects and efficacy for productive symptoms.
  • To identify unresolved questions regarding the long-term use and cost-effectiveness of atypical antipsychotics.

Summary:

  • Antipsychotics, unlike traditional neuroleptics, target receptors beyond dopamine, notably serotonin receptors.
  • These newer agents exhibit fewer extrapyramidal side effects and are effective for productive symptoms in schizophrenia, with potential benefits for resistant cases.

Related Experiment Videos

  • While precursors like sulpiride and derivatives like amisulpride exist, newer drugs like clozapine, risperidone, and olanzapine are also available, with more anticipated.

    • Impact:

    • Antipsychotics offer a promising alternative for schizophrenia treatment, addressing limitations of older drugs.
    • Further research is needed to establish the long-term efficacy, safety, and cost-benefit profile of these advanced medications for widespread clinical adoption.